Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10752789 | 1.00 | ALDH1A1 (0.38) | ALDH1A1PKMLMNATSHR | |
| SCHEMBL789124 | 1.00 | ALDH1A1 (0.38) | ALDH1A1PKMLMNATSHR | |
| SCHEMBL9567813 | 1.00 | ALDH1A1 (0.38) | ALDH1A1PKMLMNATSHR | |
| SCHEMBL789013 | 0.98 | ALDH1A1 (0.37) | ALDH1A1PKM | |
| SCHEMBL788956 | 0.98 | ALDH1A1 (0.37) | ALDH1A1PKM | |
| SCHEMBL22402473 | 0.98 | ALDH1A1 (0.37) | ALDH1A1PKM | |
| SCHEMBL788957 | 0.98 | ALDH1A1 (0.37) | ALDH1A1PKM | |
| SCHEMBL789556 | 0.96 | ALDH1A1 (0.33) | ALDH1A1PKM | |
| SCHEMBL789484 | 0.96 | ALDH1A1 (0.33) | ALDH1A1PKM | |
| SCHEMBL789485 | 0.96 | ALDH1A1 (0.33) | ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0001284-B1 | UV-LIGHT STABILIZED COMPOSITIONS CONTAINING SUBSTITUTED 2-KETO-1,4-DIAZACYCLOALKANES | The B.F. GOODRICH Company (US) | 1984-05-23 | — | — | EP | claimed |
| US-4190571-A | POLYOLEFINS | THE B. F. GOODRICH COMPANY (US) | 1980-02-26 | — | — | US | claimed |
| EP-0001284-A1 | UV-light stabilized compositions containing substituted 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1979-04-04 | — | — | EP | claimed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-31 | — | — | US | disclosed |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| US-10064879-B2 | Method for treating depression and/or depression status with substituted quinoxaline compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-09-04 | — | — | US | disclosed |
| US-20170224713-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20170224713-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| US-4297497-A | Synthesis of 2-keto-1,4-diazacycloalkanes | THE B. F. GOODRICH COMPANY | 1981-10-27 | — | — | US | disclosed |
| US-4292240-A | PHOTOSTABILIZERS FOR PLASTICS | THE B. F. GOODRICH COMPANY (US) | 1981-09-29 | — | — | US | disclosed |
| EP-0029088-A2 | Synthesis of 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1981-05-27 | — | — | EP | disclosed |
| EP-0024337-A1 | Synthesis of 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1981-03-04 | — | — | EP | disclosed |
| EP-0024337-A1 | Synthesis of 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1981-03-04 | — | — | EP | disclosed |
| US-4190571-A | POLYOLEFINS | THE B. F. GOODRICH COMPANY (US) | 1980-02-26 | — | — | US | disclosed |
| US-4167512-A | Synthesis of 2-keto-1,4-diazacycloalkanes | THE B. F. GOODRICH COMPANY (US) | 1979-09-11 | — | — | US | disclosed |
| EP-0001559-A2 | Synthesis of 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1979-05-02 | — | — | EP | disclosed |
| EP-0001284-A1 | UV-light stabilized compositions containing substituted 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1979-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | ALDH1A1 1739/4885PKM 1398/4885LMNA 258/4885 |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | ALDH1A1 2027/4885PKM 2807/4885LMNA 437/4885 |
| US-20170224713-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | ALDH1A1 2931/4885PKM 4250/4885LMNA 1124/4885 |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | ALDH1A1 2931/4885PKM 4250/4885LMNA 1124/4885 |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | MC2R, PNMT, SLC6A2 | ALDH1A1 1841/4885PKM 3047/4885LMNA 730/4885 |
| US-10064879-B2 | Method for treating depression and/or depression status with substituted quinoxaline compounds | KYNU, CRH, CHRM1 | ALDH1A1 1905/4885PKM 1347/4885LMNA 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.